Tags

Type your tag names separated by a space and hit enter

Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
Clin Pharmacol Drug Dev. 2017 Nov; 6(6):534-547.CP

Abstract

Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication-induced (medication-overuse) headache, it is the third-leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge.

Authors+Show Affiliations

Medical Toxicology and Headache Center, Policlinic Hospital, University of Modena and Reggio Emilia, Modena, Italy.Medical Toxicology and Headache Center, Policlinic Hospital, University of Modena and Reggio Emilia, Modena, Italy.Medical Toxicology and Headache Center, Policlinic Hospital, University of Modena and Reggio Emilia, Modena, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28409893

Citation

Pellesi, Lanfranco, et al. "Spotlight On Anti-CGRP Monoclonal Antibodies in Migraine: the Clinical Evidence to Date." Clinical Pharmacology in Drug Development, vol. 6, no. 6, 2017, pp. 534-547.
Pellesi L, Guerzoni S, Pini LA. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clin Pharmacol Drug Dev. 2017;6(6):534-547.
Pellesi, L., Guerzoni, S., & Pini, L. A. (2017). Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. Clinical Pharmacology in Drug Development, 6(6), 534-547. https://doi.org/10.1002/cpdd.345
Pellesi L, Guerzoni S, Pini LA. Spotlight On Anti-CGRP Monoclonal Antibodies in Migraine: the Clinical Evidence to Date. Clin Pharmacol Drug Dev. 2017;6(6):534-547. PubMed PMID: 28409893.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date. AU - Pellesi,Lanfranco, AU - Guerzoni,Simona, AU - Pini,Luigi Alberto, Y1 - 2017/04/14/ PY - 2016/11/04/received PY - 2017/01/27/accepted PY - 2017/4/15/pubmed PY - 2018/6/23/medline PY - 2017/4/15/entrez KW - CGRP KW - immunotherapy KW - migraine KW - monoclonal antibodies KW - prophylaxis SP - 534 EP - 547 JF - Clinical pharmacology in drug development JO - Clin Pharmacol Drug Dev VL - 6 IS - 6 N2 - Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication-induced (medication-overuse) headache, it is the third-leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge. SN - 2160-7648 UR - https://www.unboundmedicine.com/medline/citation/28409893/Spotlight_on_Anti_CGRP_Monoclonal_Antibodies_in_Migraine:_The_Clinical_Evidence_to_Date_ L2 - https://doi.org/10.1002/cpdd.345 DB - PRIME DP - Unbound Medicine ER -